血管性水肿治疗市场：2026-2032年全球市场预测（依药物类别、给药途径、疾病类型、最终用户和分销管道划分）

2025 年血管性水肿治疗市值为 64.7 亿美元，预计到 2026 年将成长至 76.2 亿美元，复合年增长率为 18.60%，到 2032 年将达到 213.6 亿美元。

主要市场统计数据
基准年 2025	64.7亿美元
预计年份：2026年	76.2亿美元
预测年份 2032	213.6亿美元
复合年增长率 (%)	18.60%

全面概述了血管性水肿的临床复杂性、诊断进展和治疗进展，这些正在改变血管性水肿的治疗和相关人员的优先事项。

血管性水肿是一种临床表现多样的疾病，其特征是阵发性组织肿胀、可能危及生命的呼吸道阻塞，以及涵盖遗传、免疫和特发性途径的多种诱发因素。对缓激肽介导路径的深入理解、诊断演算法的改进以及强调靶向分子干预的治疗方法的拓展，正在重塑现代医疗模式。临床医师越来越重视起效迅速、能够为高风险患者提供持续预防、且可在门诊或居家给药的治疗方法，以减少急诊医疗需求并提高患者的生活品质。

治疗创新、扩大门诊护理和不断变化的法规如何共同作用，重新定义血管性水肿的治疗模式和商业性需求？

血管性水肿的治疗格局正在经历一场变革，这主要得益于分子标靶疗法的进步、门诊治疗模式的扩展以及监管环境和支付方期望的转变。针对缓激肽路径和激肽释放酶活性的精准疗法正在重新定义临床终点，相关人员越来越关注的不仅是治疗急性发作，还包括降低发作频率和预防气道阻塞。同时，患者自行用药和居家照护的趋势正在改变产品设计重点，人们越来越重视兼具易用性、安全性和稳定性的製剂和装置。

对美国血管性水肿药物关税导致的供应链变化和采购系统调整的营运和策略影响进行评估。

美国关税趋势和贸易政策调整将对血管性水肿治疗的经济和物流环节产生重大影响，具体体现在投入成本、进口计画和供应商选择等方面。关税相关的成本压力增加，往往促使製造商和经销商调整筹资策略、加快替代供应商的认证流程，或将生产流程在地化以降低跨境关税风险。这些供应链调整可能导致重新评估库存缓衝、延长复杂生物製药的前置作业时间，以及转向更注重可靠性和可预测性的分销网络。

以细分市场主导的洞察，将治疗机制、剂型、疾病异质性、医疗保健环境和分销管道与可操作的商业化方案联繫起来。

精细化的市场细分观点揭示了临床和商业策略应如何协调一致，以应对特定的治疗类别、给药偏好、疾病病因、医疗机构和通路。对于每类药物——缓激肽受体拮抗剂、C1抑制剂和激肽释放酶抑制剂——都需要透过将机制特异性疗效与以患者为中心的终点和支付方相关指标联繫起来，来区分其价值提案。这需要产生有针对性的证据，以证明每种治疗方法在降低癫痫发作严重程度和改善长期疾病控制方面的相对优势。基于给药途径，市场通常受到注射剂（通常迅速起效）和口服剂（在便利性和依从性方面具有优势）之间实际权衡的影响。因此，研发人员需要优化製剂和给药技术，以适应预期的医疗机构环境。

制定区域策略，协调美洲、欧洲、中东和非洲以及亚太地区的监管、报销和准入方法，以最大限度地惠及病患。

区域趋势对血管性水肿治疗药物的研发重点、监管协调和准入途径有着至关重要的影响，因此美洲、欧洲、中东和非洲以及亚太地区需要采取差异化的策略。在美洲，相关人员通常致力于证明药物具有明确的临床价值，并确保其疗效符合支付方的预期，从而确保药物获得上市许可并被门诊患者接受治疗，同时支持居家给药方案，以减轻急诊护理的负担。该地区的监管审查流程通常建议采用可靠的临床终点指标和核准后安全性监测，因此，实证策略优先考虑收集真实世界数据。

领先的研发公司如何将以机制为中心的研发组合与给药创新、供应链伙伴关係以及以患者为中心的支援相结合，以实现临床和商业性应用？

血管性水肿领域主要企业的倡议包括平台投资、针对性临床开发以及建构商业生态系统。领先的研发公司优先开发针对特定机制的产品组合，同时投资于便于患者自行给药和门诊使用的製剂技术。随着企业努力降低供应链风险并确保生物製药填充、包装和低温运输配送的可靠管道，与契约製造和物流供应商建立策略合作伙伴关係正变得越来越普遍。

为经营团队提供切实可行的建议，以整合研发、供应链韧性、支付方合作以及以病人为中心的服务，从而持续推广血管性水肿治疗药物。

产业领导者应采取多管齐下的策略，整合临床差异化、供应链韧性和价值展现，并透过与支付方的合作实现这一目标。首先，优先发展能够将作用机制与具有临床意义的终点和患者报告结局（PRO）明确关联的研发项目，并确保循证方案能够涵盖急性和预防性应用场景。其次，投资于能够实现安全有效居家给药的剂型和培训项目，同时最大限度地减轻专科诊所和急救服务的负担。第三，透过认证多家供应商、尽可能探索本地生产伙伴关係以及提高整个分销链的透明度，增强供应链的柔软性并防止中断。

透过整合二手资料、有针对性的相关人员访谈和严格的检验，我们高度透明的混合调查方法能够产生以决策为中心的见解。

本研究途径结合了系统性的二级文献综述、结构化的原始研究以及严谨的检验，以确保获得可靠且具有决策意义的见解。二级研究整合了同行评审文献、监管指导文件、临床实践指南以及公开的安全性和有效性数据，以获得整体情况并识别机制差异。原始研究包括对广泛的相关人员进行半结构式访谈，这些利益相关者包括免疫学和过敏学专家、采购负责人、医院和专科诊所的临床管理人员以及患者权益倡导组织的代表，旨在识别推广应用的障碍以及治疗路径的实际情况。

结论强调了治疗创新、交付模式、支付方合作和供应弹性之间的相互作用，这对于血管性水肿治疗的实质进展至关重要。

这些分析凸显了血管性水肿治疗领域的一个策略转折点：分子层面的创新、递送优化和生态系统设计在此交汇融合，为改善患者预后和实现差异化的商业性成功创造了新的机会。标靶治疗的进步和对居家照护模式日益增长的关注，正推动临床实践向预防性管理转变；同时，需要采取谨慎的风险缓解策略，以适应供应炼和政策趋势并维持药物的可及性。有效的商业化不仅取决于分子疗效，还取决于向支付方证明其价值、为患者提供便利安全的给药方案，以及确保在各种通路中实现可靠的供应。

目录

第一章：序言

第二章：调查方法

• 调查设计
• 研究框架
• 市场规模预测
• 数据三角测量
• 调查结果
• 调查的前提
• 研究限制

第三章执行摘要

• 首席体验长观点
• 市场规模和成长趋势
• 2025年市占率分析
• FPNV定位矩阵，2025
• 新的商机
• 下一代经营模式
• 产业蓝图

第四章 市场概览

• 产业生态系与价值链分析
• 波特五力分析
• PESTEL 分析
• 市场展望
• 上市策略

第五章 市场洞察

• 消费者洞察与终端用户观点
• 消费者体验基准
• 机会映射
• 分销通路分析
• 价格趋势分析
• 监理合规和标准框架
• ESG与永续性分析
• 中断和风险情景
• 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 血管性水肿治疗市场：依药物类别划分

• 缓激肽受体拮抗剂
• C1抑制剂
• 激肽释放酶抑制剂

第九章：依给药途径分類的血管性水肿治疗市场

• 注射药物
• 口服

第十章 血管性水肿治疗市场：依疾病类型划分

• 获得
• 遗传
• 特发性

第十一章 血管性水肿治疗市场：依最终用户划分

• 居家照护
• 医院
• 专科诊所

第十二章 血管性水肿治疗市场：依通路划分

• 医院药房
• 网路药房
• 零售药房

第十三章 血管性水肿治疗市场：依地区划分

• 北美洲和南美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章 血管性水肿治疗市场：依组别划分

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 血管性水肿治疗市场：依国家划分

• 我们
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章：美国血管性水肿治疗市场

第十七章 中国血管性水肿治疗市场

第十八章 竞争格局

• 市场集中度分析，2025年
  • 浓度比（CR）
  • 赫芬达尔-赫希曼指数 (HHI)
• 近期趋势及影响分析，2025 年
• 2025年产品系列分析
• 基准分析，2025 年
• Adverum Biotechnologies, Inc.
• Argenx NV
• AstraZeneca plc
• Attune Pharmaceuticals, Inc.
• Aurobindo Pharma Ltd.
• Bayer AG
• BioCryst Pharmaceuticals, Inc.
• Cipla Limited
• CSL Behring
• Dr. Reddy's Laboratories Ltd.
• GlaxoSmithKline plc
• HAE Pharma LLC
• Intellia Therapeutics, Inc.
• Ionis Pharmaceuticals, Inc.
• KalVista Pharmaceuticals Ltd.
• Merck & Co., Inc.
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Pharming Group NV
• Pharvaris Netherlands BV
• Sanofi SA
• Sobi
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.

The Angioedema Treatment Market was valued at USD 6.47 billion in 2025 and is projected to grow to USD 7.62 billion in 2026, with a CAGR of 18.60%, reaching USD 21.36 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 6.47 billion
Estimated Year [2026]	USD 7.62 billion
Forecast Year [2032]	USD 21.36 billion
CAGR (%)	18.60%

An immersive introduction to the clinical complexity, diagnostic evolution, and therapeutic momentum transforming angioedema care and stakeholder priorities

Angioedema presents a heterogeneous clinical challenge characterized by episodic tissue swelling, potentially life-threatening airway compromise, and variable triggers that span genetic, immunologic, and idiopathic pathways. Contemporary care paradigms are being reshaped by a deeper mechanistic understanding of bradykinin-mediated pathways, improved diagnostic algorithms, and an expanding therapeutic armamentarium that emphasizes targeted molecular interventions. Clinicians increasingly prioritize rapid onset of action, durable prophylaxis for high-risk patients, and treatment regimens that support outpatient and home-based administration to reduce emergency utilization and improve quality of life.

Payers and health systems are adapting protocols to balance acute care needs against long-term management costs and patient adherence. Meanwhile, research investments are moving toward precision approaches that seek to stratify patients by underlying disease mechanism and response predictors. Translational efforts now focus on biomarker-driven diagnostics and novel delivery platforms that can address both hereditary and acquired forms of angioedema. Taken together, these forces are driving a transition from episodic rescue therapy toward integrated care pathways that emphasize prophylaxis, personalized treatment selection, and cross-disciplinary coordination among immunology, allergy, and emergency medicine specialists.

How therapeutic innovation, outpatient care expansion, and regulatory evolution are converging to redefine treatment paradigms and commercial imperatives in angioedema

The landscape for angioedema treatment is undergoing transformative shifts driven by advances in molecularly targeted therapies, expanded outpatient care models, and evolving regulatory and payer expectations. Precision therapeutics that target the bradykinin pathway and kallikrein activity are redefining clinical endpoints, with stakeholders increasingly focused on reducing attack frequency and preventing airway compromise rather than merely treating acute episodes. Simultaneously, the move toward self-administration and home-based care is altering product design priorities, favoring formulations and devices that combine ease of use with robust safety and stability profiles.

Regulatory frameworks are also maturing to accommodate novel biologics and small-molecule inhibitors, prompting sponsors to design evidence packages that emphasize patient-reported outcomes and long-term safety. In parallel, digital health tools and remote monitoring are creating opportunities for earlier intervention and improved adherence, enabling tighter integration between specialty clinics and home care providers. These shifts create new competitive dynamics, where value demonstration, real-world evidence generation, and cross-stakeholder alignment will determine which products achieve sustainable uptake across diverse care settings.

Assessing the operational and strategic consequences of tariff-driven supply chain shifts and procurement adaptations for angioedema therapeutics in the United States

Tariff dynamics and trade policy adjustments in the United States can materially influence the economics and logistics of angioedema therapeutics by affecting input costs, import timelines, and supplier selection. When tariff-related cost pressures rise, manufacturers and distributors often respond by reassessing sourcing strategies, accelerating qualification of alternative suppliers, or localizing manufacturing steps to reduce exposure to cross-border duties. These supply chain adaptations can lead to reevaluation of inventory buffers, longer lead times for complex biologics, and shifts in distribution networks that prioritize reliability and predictability.

Healthcare providers and payers may experience indirect effects as procurement processes incorporate new cost and availability considerations, prompting renegotiations of contracts or the exploration of alternative therapeutic classes where clinically appropriate. Manufacturers can mitigate tariff-related disruptions by diversifying supply chains across geographies, investing in onshore fill-finish capabilities, and enhancing transparency with trading partners to anticipate policy shifts. In addition, strategic use of advance purchase commitments and tiered pricing arrangements can preserve access in vulnerable patient populations while maintaining commercial viability under evolving tariff conditions.

Segment-driven insights that connect therapeutic mechanisms, delivery formats, disease heterogeneity, care settings, and distribution channels to pragmatic commercialization choices

A granular segmentation lens reveals how clinical and commercial strategies must align to address distinct therapeutic classes, administration preferences, disease etiologies, care settings, and distribution pathways. Based on drug class, product developers must differentiate value propositions for bradykinin receptor antagonists, C1 inhibitors, and kallikrein inhibitors by linking mechanism-specific outcomes to patient-centric endpoints and payer-relevant measures. This requires targeted evidence generation that speaks to the comparative advantages of each modality in reducing attack severity and improving long-term disease control. Based on administration route, the market is influenced by the practical trade-offs between injectable therapies that often deliver rapid onset and oral agents that offer convenience and adherence benefits; developers must therefore optimize formulation and delivery technology to match intended care settings.

Based on disease type, the needs of patients with acquired, hereditary, and idiopathic forms diverge in diagnostic complexity, genetic counseling requirements, and prophylaxis versus rescue therapy priorities, demanding differentiated clinical pathways and patient education. Based on end user, home care, hospitals, and specialty clinics present unique adoption barriers and training needs, shaping how product support programs and clinical services are structured. Based on distribution channel, hospital pharmacy, online pharmacy, and retail pharmacy dynamics influence access, reimbursement pathways, and patient convenience, requiring tailored commercial strategies that account for regulatory, logistical, and payer nuances across each channel.

Regional strategies for aligning regulatory, reimbursement, and access approaches across the Americas, Europe Middle East & Africa, and Asia-Pacific to optimize patient reach

Regional dynamics exert a defining influence on development priorities, regulatory alignment, and access pathways for angioedema treatments, requiring differentiated approaches across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, stakeholder emphasis is commonly placed on demonstrating clear clinical value and payer-aligned outcomes to secure formulary placement and outpatient adoption while also supporting home administration programs that reduce acute care burden. Regulatory review processes in this region often encourage robust clinical endpoints and post-approval safety monitoring, shaping evidence strategies that prioritize real-world data collection.

Across Europe, Middle East & Africa, diverse national regulatory regimes and procurement models necessitate flexible market-entry strategies and tailored health-technology assessment dossiers. Manufacturers must be prepared to engage diverse payer panels and adopt adaptive pricing approaches to accommodate public tendering processes and regional reimbursement variability. In the Asia-Pacific region, rapid innovation adoption in some markets is counterbalanced by infrastructure and access disparities in others, creating opportunities for tiered market entry, local partnerships, and capacity-building initiatives that support training for specialty clinics and home-care networks. Across all regions, coordinated regulatory planning and early payer engagement enhance the likelihood of timely access for patients.

How leading developers are pairing mechanism-focused portfolios with delivery innovations, supply-chain partnerships, and patient-centric support to win clinical and commercial adoption

Key company-level behaviors in the angioedema landscape reflect a combination of platform investment, targeted clinical development, and commercial ecosystem building. Leading developers are prioritizing mechanism-specific portfolios while investing in formulation technologies that facilitate self-administration and outpatient use. Strategic alliances with contract manufacturing and logistics providers are increasingly common as firms seek to de-risk supply chains and secure reliable channels for biologic fill-finish and cold-chain distribution.

Commercially, firms are creating integrated patient support services that combine training, adherence tools, and reimbursement navigation to lower barriers to adoption among home care users and specialty clinics. On the evidence front, sponsors are expanding real-world data programs and patient-reported outcome initiatives to supplement pivotal clinical studies and to meet payer expectations for longitudinal effectiveness and safety. Competitive differentiation is emerging through service models as much as product attributes, with successful organizations demonstrating the ability to align clinical benefits with pragmatic delivery and support systems that resonate with clinicians, payers, and patients alike.

Actionable recommendations for executives to align R&D, supply chain resilience, payer engagement, and patient-centric services for sustainable angioedema product adoption

Industry leaders should adopt a multi-dimensional strategy that integrates clinical differentiation, supply resilience, and payer-aligned value demonstration. First, prioritize development programs that clearly link mechanism of action to clinically meaningful endpoints and patient-reported outcomes, ensuring that evidence generation plans address both acute and prophylactic use cases. Second, invest in delivery formats and training programs that enable safe, effective home administration while minimizing the burden on specialty clinics and emergency services. Third, build supply-chain flexibility by qualifying multiple suppliers, exploring local manufacturing partnerships where feasible, and enhancing visibility across distribution layers to preempt disruptions.

Additionally, engage payers early with transparent value dossiers and real-world evidence plans that demonstrate cost-offsets associated with reduced emergency interventions and improved work productivity. Strengthen commercial propositions by aligning distribution strategies with channel-specific access considerations, coordinating with hospital pharmacies, online dispensaries, and retail networks to optimize availability. Finally, develop service-oriented differentiation-patient support, digital adherence tools, and clinician education-to accelerate uptake and sustain long-term adherence across diverse patient cohorts.

A transparent mixed-methods methodology integrating secondary synthesis, targeted stakeholder interviews, and rigorous triangulation to produce decision-focused insights

The research approach combines systematic secondary review, structured primary inquiry, and rigorous triangulation to ensure robust, decision-grade findings. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, clinical practice statements, and publicly available safety and efficacy data to map the clinical landscape and identify mechanistic differentiators. Primary research involved semi-structured interviews with a cross-section of stakeholders, including specialists in immunology and allergy, procurement officials, clinical operations leaders from hospitals and specialty clinics, and patient advocacy representatives to surface adoption barriers and care pathway realities.

Data were triangulated through cross-validation of clinical inputs, supply-chain assessments, and payer perspectives to reconcile divergent viewpoints and highlight consensus-driven implications. Segmentation analysis applied diagnostic, therapeutic, and channel lenses to isolate differential needs across bradykinin receptor antagonists, C1 inhibitors, and kallikrein inhibitors as well as injectable versus oral administration, hereditary versus acquired and idiopathic disease types, and the roles of home care, hospitals, and specialty clinics. Quality control measures included methodological audits, interview verification, and iterative expert review to ensure findings are actionable and replicable.

Concluding synthesis emphasizing the interplay of therapeutic innovation, delivery models, payer engagement, and supply resilience required for meaningful angioedema care advancement

The cumulative analysis underscores a strategic inflection point for angioedema treatment where molecular innovation, delivery optimization, and ecosystem design converge to create new opportunities for improved patient outcomes and differentiated commercial success. Advances in targeted therapeutics and an increased emphasis on home-based care models are shifting clinical practice toward proactive management, while supply chain and policy dynamics require deliberate mitigation strategies to sustain access. Effective commercialization will depend not solely on molecular efficacy but on the ability to demonstrate value to payers, deliver convenient and safe administration options to patients, and ensure distribution reliability across diverse channels.

Looking ahead, organizations that couple robust clinical programs with adaptive supply chains and comprehensive patient support mechanisms will be best positioned to translate scientific progress into meaningful care improvements. Cross-disciplinary collaboration among developers, clinicians, payers, and patient groups will remain essential to align incentives and expedite adoption of therapies that reduce disease burden and enhance long-term quality of life.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Angioedema Treatment Market, by Drug Class

• 8.1. Bradykinin Receptor Antagonists
• 8.2. C1 Inhibitors
• 8.3. Kallikrein Inhibitors

9. Angioedema Treatment Market, by Administration Route

• 9.1. Injectable
• 9.2. Oral

10. Angioedema Treatment Market, by Disease Type

• 10.1. Acquired
• 10.2. Hereditary
• 10.3. Idiopathic

11. Angioedema Treatment Market, by End User

• 11.1. Home Care
• 11.2. Hospitals
• 11.3. Specialty Clinics

12. Angioedema Treatment Market, by Distribution Channel

• 12.1. Hospital Pharmacy
• 12.2. Online Pharmacy
• 12.3. Retail Pharmacy

13. Angioedema Treatment Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Angioedema Treatment Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Angioedema Treatment Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. United States Angioedema Treatment Market

17. China Angioedema Treatment Market

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025
• 18.5. Adverum Biotechnologies, Inc.
• 18.6. Argenx NV
• 18.7. AstraZeneca plc
• 18.8. Attune Pharmaceuticals, Inc.
• 18.9. Aurobindo Pharma Ltd.
• 18.10. Bayer AG
• 18.11. BioCryst Pharmaceuticals, Inc.
• 18.12. Cipla Limited
• 18.13. CSL Behring
• 18.14. Dr. Reddy's Laboratories Ltd.
• 18.15. GlaxoSmithKline plc
• 18.16. HAE Pharma LLC
• 18.17. Intellia Therapeutics, Inc.
• 18.18. Ionis Pharmaceuticals, Inc.
• 18.19. KalVista Pharmaceuticals Ltd.
• 18.20. Merck & Co., Inc.
• 18.21. Novartis AG
• 18.22. Otsuka Pharmaceutical Co., Ltd.
• 18.23. Pfizer Inc.
• 18.24. Pharming Group N.V.
• 18.25. Pharvaris Netherlands B.V.
• 18.26. Sanofi S.A.
• 18.27. Sobi
• 18.28. Takeda Pharmaceutical Company Limited
• 18.29. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL ANGIOEDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL ANGIOEDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 13. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY C1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY KALLIKREIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ACQUIRED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ACQUIRED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ACQUIRED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HEREDITARY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HEREDITARY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HEREDITARY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY IDIOPATHIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY IDIOPATHIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY IDIOPATHIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 50. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 51. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 52. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 53. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 54. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 55. AMERICAS ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 56. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 57. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 58. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 59. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 60. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 61. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 62. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 63. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 64. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 65. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 66. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 67. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 68. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 69. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 70. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 71. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 72. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 73. EUROPE, MIDDLE EAST & AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 74. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 75. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 76. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 77. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 78. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 79. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 80. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 81. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 82. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 83. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 84. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 85. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 86. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 87. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 88. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 89. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 90. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 91. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 92. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 93. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 94. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 95. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 96. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 97. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 98. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 99. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 100. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 101. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 102. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 103. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 104. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 105. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 106. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 107. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 108. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 109. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 110. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 111. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 112. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 113. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 114. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 115. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 116. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 117. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 118. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 119. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 120. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 121. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 122. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 123. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 124. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 125. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 126. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 127. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 128. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 129. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 130. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 131. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 132. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 133. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 134. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 135. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 136. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 137. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 138. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 139. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 140. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 141. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 142. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 143. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 144. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 145. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
• TABLE 146. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 147. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)